• Molnupiravir Protects Mice from Bourbon Virus

  2026-08-22

  The reference study provides the first preclinical evidence that molnupiravir can both prevent and treat lethal Bourbon virus infection in a susceptible mouse model. Its combination of cell-based screening, post-exposure intervention, virological measurements, hematological endpoints, and tissue pathology offers a useful framework for evaluating therapies against emerging tick-borne viruses.

• TRIM26–NDP52 Autophagy in PRV Infection

  2026-08-21

  The reference study identifies TRIM26 as a proviral factor in pseudorabies virus infection rather than simply an antiviral regulator. Its central mechanistic finding is that TRIM26 recruits NDP52 to promote selective autophagic degradation of MAVS, weakening RIG-I-dependent type I interferon signaling and enabling viral replication.

• Anti-RPS6 Antibody: A Systems Assay Guide

  2026-08-20

  The Anti-RPS6 antibody MA4974 enables integrated Western blot, immunofluorescence, and immunoprecipitation analysis of RPS6 in signaling, ribosome biogenesis, and PDAC models. This guide explains how to interpret total RPS6 as one layer of a causal assay framework rather than as a standalone proxy for translation or pathway activation.

• PUFA-PL Enzymes in Rice Blast Pathogenicity

  2026-08-20

  The 2024 Mycology study connects Fad2- and Acsl4-dependent polyunsaturated fatty acid phospholipid production with ferroptosis-associated development and pathogenicity in Magnaporthe oryzae. Genetic disruption, targeted lipidomics, iron-mediated rescue, and protein-interaction analysis together identify PUFA-PL metabolism as a promising but not yet fully validated disease-control target.

• Budoids Reveal Signaling Centers in Limb Morphogenesis

  2026-08-19

  Skoufa and colleagues developed mESC-derived 3D “budoids” that combine AER-like, surface ectoderm, and mesodermal properties to model epithelial–mesoderm interactions during limb-like morphogenesis. The organoids reveal that AER-like cells can coordinate both local cell identity and broader tissue polarization, offering a quantitative platform for studying signaling-center function.

• SLU-PP-332: ERRα/β/γ Agonist Research Guide

  2026-08-19

  SLU-PP-332 is a synthetic ERRα ERRβ ERRγ agonist investigated as a regulator of mitochondrial respiration and skeletal-muscle metabolism. Preclinical evidence supports receptor activation and cellular metabolic effects, but it does not establish a human dosage, clinical efficacy, or long-term safety.

• Palonosetron and CINV: Evidence from a Drug Profile

  2026-08-18

  This review synthesizes the pharmacology, clinical evidence, and tolerability of palonosetron hydrochloride for chemotherapy-induced nausea and vomiting (CINV), emphasizing its high 5-HT3-receptor affinity, long half-life, and distinctive allosteric binding. Its practical value lies in connecting receptor-level properties with prevention of both acute and delayed emesis while clarifying the limits of cross-trial comparisons.

• MK-0812: CCR2 Precision in the Gut–Liver Axis

  2026-08-18

  The gut–liver axis is reshaping MASH research, but its inflammatory effector pathways remain underdefined. This article examines how MK-0812, a selective CCR2 antagonist, can help translational researchers test monocyte trafficking as a downstream immune component of TM6SF2–LPA axis dysfunction without overstating current evidence.

• Extracellular Vesicle Inhibition in TNBC

  2026-08-17

  McNamee et al. systematically compared several inhibitors and combinations for suppressing extracellular vesicle release from triple-negative breast cancer models. The study shows that broad reduction of vesicle output, rather than selective removal of one proposed subpopulation, may be necessary to limit the transfer of aggressive traits to recipient cells.

• MK-0812: Mapping CCR2 in MASH Models

  2026-08-17

  MK-0812 is a selective CCR2 antagonist for testing monocyte trafficking in MASH research. This article presents a causal assay framework that separates gut-derived lipid signals, microbiota effects, and hepatic immune recruitment rather than treating steatohepatitis as a single endpoint.

• RG7388: Selective MDM2 Antagonist for p53

  2026-08-16

  RG7388 is an oral, selective MDM2 antagonist that activates the p53 pathway by disrupting the p53-MDM2 interaction. Product data report nanomolar biochemical and cellular activity, while current evidence remains primarily preclinical and is strongest in wild-type p53 models.

• Calcium Control of Amyloid-β Aggregation

  2026-08-15

  The reference study combines supercritical angle Raman and fluorescence methods with microscopy to distinguish amyloid-β behavior at lipid interfaces from signals in bulk solution. It shows that CaCl2 can form an interfacial calcium layer that protects membranes, while its effect is weaker for Aβ1–40 than for Aβ1–42 and depends on the aggregation state and timing of calcium exposure.

• GSK-923295 for CENP-E Mitosis Studies

  2026-08-15

  GSK-923295 is a mechanistically focused CENP-E inhibitor for testing chromosome congression, mitotic checkpoint behavior, and cell-cycle arrest in mitosis. Its small-molecule timing complements degron and RNAi approaches, enabling side-by-side separation of motor-dependent alignment defects from centromere-architecture phenotypes.

• Intestinal TM6SF2 and the Gut–Liver Axis in MASH

  2026-08-14

  This Nature Metabolism study identifies intestinal TM6SF2 as a protective regulator of MASH through coordinated control of epithelial lipid handling, barrier integrity, microbiota, and lysophosphatidic acid signaling. Its genetic, germ-free, co-housing, and pharmacological experiments support a gut-derived mechanism that may be tested through microbiota or LPA-receptor interventions.

• DOPE for Nucleic Acid Delivery: Mechanism and Limits

  2026-08-13

  1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is a fusogenic helper phospholipid for cationic liposomes and lipid nanoparticle formulations. Its product-reported solvent profile, storage requirement, and ≥98% purity define practical handling boundaries for nucleic acid delivery workflows.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page